Treatment with pimecrolimus cream 1% clears irritant dermatitis of the periocular region, face and neck

International Journal of Dermatology

Volumn 47, Issue 9, 2008, Pages 960-964

  Mensing, C O ^a   Mensing, C H ^a   Mensing, Hartwig ^a,b  

^a Dermatological Consultancy   (Germany)

^b NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABITIMA; PIMECROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EVENING DOSAGE; FEMALE; HUMAN; IRRITANT DERMATITIS; MALE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MORNING DOSAGE; OUTCOME ASSESSMENT; RELAPSE; SCORING SYSTEM; SEBORRHEIC DERMATITIS; SKIN BURNING SENSATION; SKIN PRURITUS; SKIN SWELLING; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY, NEEDLE; DERMATITIS, IRRITANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FACIAL DERMATOSES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NECK; OINTMENTS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 50149089995     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2008.03634.x     Document Type: Article

References (32)

1. Uehara M. Infraorbital fold in atopic dermatitis. Arch Dermatol 1981; 117: 627-629.
2. Guin JD. Eyelid dermatitis: Experience in 203 cases. J Am Acad Dermatol 2002; 47: 755-765.
3. Zug KA, Palay DA, Rock B. Dermatologic diagnosis and treatment of itchy red eyelids. Surv Ophthalmol 1996; 40: 293-306.
4. Rapaport MJ, Rapaport V. Eyelid dermatitis to red face syndrome to cure: clinical experience in 100 cases. J Am Acad Dermatol 1999; 41: 435-442.
5. Velangi SS, Humphreys F, Beveridge GW. Periocular dermatitis associated with prolonged use of a steroid eye ointment. Clin Exp Dermatol 1998; 23: 297-298.
6. Malik R, Quirk CJ. Topical applications and perioral dermatitis. Australas J Dermatol 2000; 41: 34-38.
7. Uehara M, Sugiura H, Sakurai K. A trial of oolong tea in the management of recalcitrant atopic dermatitis. Arch Dermatol 2001; 137: 42-43.
8. Lackenbacher RS. Treatment of various skin diseases; topical application of ichthyol. Med Times 1956; 84: 1235-1241.
9. Gupta AK, Chow M. Pimecrolimus: A review. J Eur Acad Dermatol Venereol 2003; 17: 493-503.
10. Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1%: A nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003; 111: 1153-1168.
11. Graham-Brown RA, Grassberger M. Pimecrolimus: A review of pre-clinical and clinical data. Int J Clin Pract 2003; 57: 319-327.
12. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277-284.
13. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology. Br J Dermatol 1999; 141: 264-273.
14. FDA. licensing review of pimecrolimus. Source: http://www.fda.gov/cder/ approval/index.htm. Accessed 17 October.
15. Paul C, Graeber M, Stuetz A. Ascomycins. promising agents for the treatment of inflammatory skin diseases. Expert Opin Invest Drugs 2000; 9: 69-77.
16. Belsito DV, Fowler JF Jr, Marks JG Jr, et al. Pimecrolimus cream 1%: A potential new treatment for chronic hand disease. Cutis 2004; 73: 31-38.
17. Eichenfeld LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504.
18. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20: 233-241.
19. Mrowietz U, Graeber M, Brautigam M, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992-996.
20. Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144: 788-794.
21. Meurer M, Fölster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology 2002; 205: 271-277.
22. Williams H. New treatments for atopic dermatitis. BMJ 2002; 324: 1533-1534.
23. Schopf RE. Pimecrolimus. Novartis. Curr Opin Invest Drugs 2002; 3: 720-724.
24. Eberlein-Konig B, Spiegl A, Przybilla B. Change of skin roughness due to lowering air humidity in climate chamber. Acta Derm Venereol 1996; 76: 447-449.
25. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; 114: 146-148.
26. Svensson A, Möller H. Eyelid dermatitis: The role of atopy and contact dermatitis. Contact Dermatitis 1986; 15: 178-182.
27. Franke W, Kuhn A, Megahed M, et al. [Periorbital edema as the initial symptom of lupus erythematosus profundus. Case report and discussion of the literature. Article in German]. Hautarzt 1999; 50: 889-892.
28. Krengel S, Kölmel KF. [Differential diagnosis of eyelid edema.] Article in German. Hautarzt 1996; 47: 2-19.
29. Bornhovd E, Burgdorf WH, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001; 45: 736-743.
30. Flanagan WM, Corthesy B, Bram RJ, et al. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporine A. Nature 1991; 352: 803-807.
31. Kay JE. Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Biochem J 1996; 314: 361-385.
32. Dissemond J, Goos M, Wagner SN. Pimecrolimus (SDZ ASM 981). Current state of research. Dtsch Med Wochenschr 2002; 127: 1199-1203.